ERBB2 and breast cancer: A total of 703 patients with ER‐positive, HER2‐negative, T1‐3N0M0 BC were included in this study, among which 451 patients had low‐risk (RS, 0–25) and 252 patients had high‐risk (RS, 26–100) BC.